6xcc: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6xcc' size='340' side='right'caption='[[6xcc]], [[Resolution|resolution]] 1.90Å' scene=''> | <StructureSection load='6xcc' size='340' side='right'caption='[[6xcc]], [[Resolution|resolution]] 1.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'> | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XCC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XCC FirstGlance]. <br> | ||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9Å</td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UZV:N-hydroxy-5-sulfanylpentanamide'>UZV</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UZV:N-hydroxy-5-sulfanylpentanamide'>UZV</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xcc OCA], [https://pdbe.org/6xcc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xcc RCSB], [https://www.ebi.ac.uk/pdbsum/6xcc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xcc ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xcc OCA], [https://pdbe.org/6xcc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xcc RCSB], [https://www.ebi.ac.uk/pdbsum/6xcc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xcc ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 26: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Allen KN]] | [[Category: Allen KN]] | ||
[[Category: Tararina MA]] | [[Category: Tararina MA]] | ||
Latest revision as of 12:16, 9 October 2024
Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 21Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with covalent inhibitor 21
Structural highlights
Publication Abstract from PubMedBotulinum neurotoxins have remarkable persistence ( approximately weeks to months in cells), outlasting the small-molecule inhibitors designed to target them. To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive warhead-were designed to leverage both affinity and reactivity. A series of first-generation bifunctional inhibitors was achieved through structure-based inhibitor design. Through X-ray crystallography, engagement of both the catalytic Zn(2+) and Cys165 was confirmed. A second-generation series improved on affinity by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and in vitro evaluation against the C165S mutant. Finally, a third-generation inhibitor was shown to have good cellular activity and low toxicity. In addition to our findings, an alternative method of modeling time-dependent inhibition that simplifies assay setup and allows comparison of inhibition models is discussed. Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.,Lin L, Olson ME, Sugane T, Turner LD, Tararina MA, Nielsen AL, Kurbanov EK, Pellett S, Johnson EA, Cohen SM, Allen KN, Janda KD J Med Chem. 2020 Sep 18. doi: 10.1021/acs.jmedchem.0c01006. PMID:32886509[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||